What a journey — and what a thoughtful, detailed history. It's clear a lot has been navigated already, and asking about letrozole combinations shows real engagement with exploring next steps.
While no specific member experiences with letrozole plus everolimus or letrozole plus abemaciclib have been shared here, these Show Full Answer
What a journey — and what a thoughtful, detailed history. It's clear a lot has been navigated already, and asking about letrozole combinations shows real engagement with exploring next steps.
While no specific member experiences with letrozole plus everolimus or letrozole plus abemaciclib have been shared here, these combinations are being investigated for recurrent endometrial cancer, particularly for hormone receptor-positive cases. They fall under the category of targeted/hormone therapy combinations.
Given the treatment history — especially the prior pembrolizumab discontinuation due to kidney complications — any new treatment discussion with an oncologist would need to carefully weigh kidney function and prior toxicities. A few things worth raising with an oncologist given this specific situation:
- Biomarker status — MMR-proficient/MSI-stable status limits some immunotherapy options, making hormone-based and targeted combinations more relevant to explore
- Clinical trials — These combinations may be available through trials, which could be worth investigating given the number of prior lines of treatment
- Renal history — Prior kidney complications mean any new regimen needs careful monitoring and dosing consideration
Connecting with a gynecologic oncologist who specializes in recurrent disease, or seeking a second opinion at a major cancer center, could open doors to emerging options like these combinations.
September 25